Keyphrases
Improved Outcomes
50%
Frail Elderly
50%
Postmenopausal Women
50%
Hospitalization
50%
Rivaroxaban
50%
Development Implementation
50%
Older Widows
50%
Transitional Care
50%
Development Evaluation
50%
Netherlands
50%
Healthcare Expenditure
50%
Spouses
50%
Dabigatran
50%
Model-based Economic Evaluation
50%
Oral Anticoagulant Therapy
50%
Ethical Argumentation
50%
Value of Information Analysis
50%
Abnormal Uterine Bleeding
50%
Oral Antiplatelet
50%
Cost of Dying
50%
Medical Care Expenditure
50%
Adverse Outcomes
40%
Vitamin K Antagonists
35%
Non-participation
33%
Anticoagulation
28%
Long-term Care
25%
Dual Antiplatelet Therapy
25%
Anticoagulants
25%
Informal Care
22%
Bleeding
21%
Context-independent
21%
Non-frail
20%
Two-sample
20%
Healthcare Professionals
20%
Risk Ratio
20%
Expenditure Level
16%
Nonmaleficence
16%
Novel Oral Anticoagulants
16%
Drug Class
16%
Pivotal Trial
16%
Principle of Autonomy
16%
Clinical Uncertainty
16%
Ethical Principles
16%
Oral Anticoagulant Drugs
16%
Oral Anticoagulants
16%
Risk-benefit
14%
Extracranial Hemorrhage
14%
Economic Time
12%
Traffic Accidents
12%
Uterine Bleeding
12%
Medicine and Dentistry
Health Care
100%
Health Service
55%
Adverse Outcome
50%
Transitional Care
50%
Premenopause
50%
Rivaroxaban
50%
Demography
50%
Antiplatelet
50%
Antithrombotic
50%
Uterus Bleeding
50%
Health Care Cost
50%
Long-Term Care
38%
Anticoagulant
37%
Vitamin K Antagonist
35%
Anticoagulation
28%
Ciclonicate
21%
Geriatrics
12%
Multiple Chronic Conditions
12%
Menstruation
12%
Cerebral Hemorrhage
7%
Brain Ischemia
7%
Circannual Rhythm
7%
Marital Status
5%
Mixed Model
5%
Medical Care
5%
